Gentian Diagnostics Valuation
Is 6FK undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6FK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6FK (€3.56) is trading above our estimate of fair value (€1.15)
Significantly Below Fair Value: 6FK is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6FK?
Other financial metrics that can be useful for relative valuation.
| What is 6FK's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | n/a |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.8x |
| Enterprise Value/EBITDA | 60.1x |
| PEG Ratio | 8.5x |
Price to Sales Ratio vs Peers
How does 6FK's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.1x | ||
PHH2 Paul Hartmann | 0.3x | n/a | €724.6m |
PUS PULSION Medical Systems | 3.7x | n/a | €132.7m |
AAQ1 aap Implantate | 1.9x | n/a | €22.2m |
M3V MeVis Medical Solutions | 2.5x | n/a | €44.4m |
6FK Gentian Diagnostics | 4.4x | 24.6% | €672.4m |
Price-To-Sales vs Peers: 6FK is expensive based on its Price-To-Sales Ratio (4.4x) compared to the peer average (2.1x).
Price to Earnings Ratio vs Industry
How does 6FK's PE Ratio compare vs other companies in the DE Medical Equipment Industry?
Price-To-Sales vs Industry: 6FK is expensive based on its Price-To-Sales Ratio (4.4x) compared to the European Medical Equipment industry average (3.7x).
Price to Sales Ratio vs Fair Ratio
What is 6FK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 4.4x |
| Fair PS Ratio | 2x |
Price-To-Sales vs Fair Ratio: 6FK is expensive based on its Price-To-Sales Ratio (4.4x) compared to the estimated Fair Price-To-Sales Ratio (2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.